Financial Shenanigans
Figures converted from INR at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.
Financial Shenanigans
Waaree Energies earns a Forensic Risk Score of 48 — Elevated. The core reported financials pass most earnings-quality tests: operating cash flow exceeds net income consistently (1.6x in FY25, 1.9x three-year average), accrual ratios are negative, and debtor days are stable. However, three linked concerns pull the score into elevated territory: (1) a live US Customs and Border Protection investigation (EAPA Case 8163, initiated September 2025) alleging evasion of anti-dumping duties on solar cells, which carries material legal, financial, and reputational risk; (2) volatile and opaque other income that inflated FY24 earnings by $6.9M (37% of operating profit); and (3) promoter-dominated governance with an executive director on the audit committee. The single data point that would most change this grade is the outcome of the CBP investigation — an adverse finding could push the score to High; resolution without penalty would bring it toward Watch.
Forensic Risk Score
Red Flags
Yellow Flags
3Y CFO / Net Income
3Y FCF / Net Income
Accrual Ratio (FY25)
Breeding Ground
Waaree's governance structure creates moderate breeding-ground risk — not because of documented misconduct, but because the structural conditions that make shenanigans easier to execute are present.
The Doshi family controls 64% of shares and occupies two of four executive board seats. The Chairman and Managing Director, Dr. Hitesh Doshi, has served since 2007 and holds the CSR committee chair. His brother Viren is a whole-time director with 67% board meeting attendance in FY25 — the lowest on the board. An executive director (Hitesh Mehta) sits on the audit committee, which while permitted under Indian regulations, weakens the independence of the oversight function. These are common patterns in Indian promoter-led companies and do not by themselves indicate misconduct. However, they reduce the institutional friction that would slow or surface accounting aggression if it occurred.
The auditor is SRBC & Co LLP (EY network), a top-tier firm. No qualification, emphasis of matter, or adverse observation has been reported. Auditor non-audit fees are modest in absolute terms but the ratio (56% of audit fees) plus $0.46M in IPO-related fees is worth monitoring. The CARE A+ / A1+ credit rating upgrade validates external comfort with credit quality.
The most significant breeding-ground signal is management's explicit EBITDA-guidance approach. CEO Amit Paithankar stated on the Q4 FY25 call: "Our key control variable is going to be EBITDA. And that's going to drive how we are going to manufacture." When the primary incentive metric is a non-GAAP measure, the classification of items between operating and non-operating, and between revenue and other income, becomes a more sensitive forensic question.
Earnings Quality
Reported earnings pass most quality tests, but elevated other income and the CBP investigation create two distinct areas of concern.
Revenue growth vs receivables: Clean. Debtor days were 31 in FY24 and 30 in FY25 on 27% revenue growth. This is a strong signal that revenue is being collected, not parked in receivables. The retail segment operates on a "book and ship" basis with full payment before shipment, per management's Q4 FY25 commentary.
Other income: Yellow flag. Other income has been volatile and material. In FY24, it reached $6.9M — 37% of operating profit and 45% of pre-tax profit. Within FY24, $4.4M (63% of the annual figure) landed in Q4 alone. By FY25, other income dropped to $4.7M (15% of operating profit), and in Q3 FY26, it turned negative at -$1.1M. The company has not clearly disclosed the composition of other income in investor presentations. Possible components include interest income on IPO proceeds parked in term deposits, IRA (Inflation Reduction Act) manufacturing credits from the US facility, foreign exchange gains/losses, and investment income. The Q3 FY26 negative figure suggests FX losses or mark-to-market reversals.
The Q4 FY24 spike is forensically significant because it coincided with a quarter where operating profit ($5.0M) was the weakest of H2 FY24. Without the $4.4M other income, PBT would have been $3.5M instead of $7.9M — a 55% haircut. This does not prove manipulation, but it demonstrates that FY24 bottom-line quality was materially dependent on below-the-line items.
Margin expansion: Appears operationally driven. OPM expanded from 14% (FY24) to 19% (FY25) and further to 23-25% in recent quarters. This is supported by: (a) 5.4 GW cell production coming online, reducing procurement costs; (b) operating leverage on higher volumes (module production up 94% YoY in Q3 FY26); (c) favorable DCR (Domestic Content Requirement) pricing for Indian-cell modules at ~$0.27/watt. The CFO confirmed back-to-back hedging on commodity procurement against orders, limiting gross margin volatility.
Capex and capitalization: Requires monitoring. Fixed assets grew from $17.4M (FY24) to $47.4M (FY25), with CWIP at $22.0M. Depreciation was $4.7M on an asset base that averaged ~$32M during the year. Capex-to-depreciation is running at approximately 8x, which is elevated but expected during a capacity-building cycle (6 GW wafer-cell-module, US expansion, battery facility, electrolyzer plant). The question is whether all capitalized amounts represent productive assets or whether any operating costs are being parked in CWIP. The rapid timeline of multiple concurrent megaprojects warrants investor scrutiny as they become operational.
Cash Flow Quality
Operating cash flow is strong and passes core quality tests, but free cash flow turned negative in FY25 as the capex cycle accelerated.
CFO/NI is healthy. The three-year average (FY23-25) is 1.90x — net income is well-supported by cash generation. FY25 alone was 1.64x. This ratio has declined from 3.12x in FY23 as the profit base expanded, but it remains above 1.0x, which is the critical threshold.
FCF turned negative in FY25. Free cash flow (CFO minus capex) was -$1.3M as capex consumed $38.3M (CFI was -$79.6M but includes investments and acquisitions). This is entirely explained by the capacity expansion: 5.4 GW cell plant, US facility ramp-up, 6 GW wafer-cell-module complex, and multiple adjacent ventures (batteries, inverters, electrolyzers). The IPO raised significant capital specifically for these purposes, and the CARE monitoring report confirmed IPO proceeds are being deployed as stated with unutilized amounts in term deposits.
Working capital contribution: Clean. DPO was 91 days in FY25 versus 84 days in FY24 — a modest increase, not a payable-stretching alarm. Inventory days improved from 108 to 96. The cash conversion cycle contracted from 55 to 35 days. There is no evidence of unsustainable working-capital lifelines propping up CFO.
No evidence of factoring or securitization. Management stated on earnings calls that retail orders are shipped only after full payment, and project orders carry 5-15% advances. There is no disclosure of receivable sales programs or supplier finance arrangements.
Financing inflows are transparent. The $47.2M CFF in FY25 is primarily attributable to IPO proceeds and incremental borrowings (from $6.6M to $14.0M). No boomerang transactions or disguised financing observed.
Metric Hygiene
The primary metric concern is the centrality of EBITDA guidance to the investment narrative. While EBITDA is a legitimate operating metric, Waaree's definition has not been independently audited as a non-GAAP reconciliation. The CFO stated EBITDA is calculated as "profit before taxes plus finance costs, depreciation, and amortization" — a standard formulation. However, the inclusion or exclusion of other income (IRA credits, FX, investment income) creates a grey zone. On the Q4 FY25 call, CEO Paithankar explicitly said the EBITDA guidance does not include "exceptional other income," but $1.6M of other income was reported in Q4 FY25 itself.
No metrics have been discontinued or redefined between periods. The order book disclosure has been consistent in format. These are positive hygiene signals.
CBP Investigation — EAPA Case 8163 (September 2025): US Customs imposed interim measures on Waaree based on "reasonable suspicion" of evasion of anti-dumping and countervailing duties on solar cells originating from China/Southeast Asia. Allegations include mislabeling Chinese-made cells as Indian-origin. Waaree has stated it will "cooperate fully" with authorities and that investment plans are unaffected. The investigation is ongoing. An adverse finding could result in triple-digit tariff penalties on historical imports, impairment of US order book, and reputational damage.
Supply Chain / Forced Labor Risk: Bloomberg News reported that Waaree shipped millions of panels to the US containing components from a Chinese company whose products were repeatedly denied US entry over forced labor concerns (Uyghur Forced Labor Prevention Act). Waaree has since invested in non-Chinese polysilicon supply (United Solar Holdings, Oman) and is restructuring supply chains. This is not an accounting shenanigan but a legal and disclosure risk that could crystallize into material financial exposure.
What to Underwrite Next
Highest-priority items to track:
CBP EAPA Case 8163 outcome. Monitor quarterly for interim measures, final determination, and potential duty assessments. A finding of duty evasion would require: (a) restatement of import duties, (b) potential penalties, (c) impairment of US order book, and (d) reputational spillover to other markets. The signal that would downgrade the forensic grade to High: CBP issues a final affirmative determination with duty assessments exceeding $12M.
Other income composition. Demand disclosure of other income breakdown: interest income, IRA credits, FX gains/losses, investment gains, and any related-party items. Track whether Q3 FY26's -$1.1M signals a structural reversal or one-time FX hit.
Cell utilization trajectory. The 5.4 GW cell plant operated at 56% utilization in Q3 FY26 (though management claimed 80%+ run-rate as of January 2026). If utilization stalls, the margin expansion story falters and capitalized costs become harder to justify.
CWIP-to-asset conversion. $22.0M CWIP in FY25 and $21.3M in H1 FY26. Monitor whether CWIP declines as projects reach commissioning dates (FY27 target for wafer-cell-module complex, batteries, electrolyzers). Persistent or growing CWIP relative to commissioning timelines would be a yellow flag.
IPO proceeds utilization. CARE monitoring report confirms partial deployment. Track deviation from stated objectives, particularly the $33.3M earmarked for the Odisha facility.
Signal that would upgrade the grade: CBP investigation resolved without penalty; cell utilization exceeds 85% sustained; other income stabilizes as a small percentage of PBT; CWIP converts to revenue-generating assets on stated timelines.
Signal that would downgrade the grade: CBP adverse finding; other income proves to include undisclosed related-party items or recycled gains; cell plant utilization stalls below 70%; CWIP grows without corresponding asset commissioning; auditor issues emerge.
The accounting risk at Waaree is not a thesis breaker — it is a position-sizing limiter. The core business (modules + cells) generates genuine cash from real manufacturing activity, and CFO/NI ratios confirm this. But the CBP investigation adds a binary legal risk that is difficult to underwrite, the other-income volatility makes quarter-to-quarter earnings comparisons unreliable, and the promoter-dominated governance reduces the institutional check on capital allocation as the company deploys $175M+ across multiple megaprojects simultaneously. An investor comfortable with the business thesis should haircut the US order book contribution, normalize for other-income volatility, and track CWIP conversion as the primary near-term forensic indicators.